MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Gastroenterology_Gastrointestinal (to include Liver, Pancreas & metabolic dysfunction-associated steatotic liver disease (MASLD), Gout, MASH (Metabolic dysfunction-associated steatohepatitis), formerly, NASH (Non-Alcoholic SteatoHepatitis)Non-Alcoholic SteatoHepatitis (NASH)
89bio, Inc. (Nasdaq: ETNB)
Organization & Developments: 89bio
Parents
89bio, Inc. (Nasdaq: ETNB)
Children
2019: 89Bio And BIO89-100 In Severe Hypertriglyceridemia_seekingalpha.com
2021: 89bio: NASH Drug Developer With Differentiated Profile
2022: 89bio Still Has A Chance As NASH Race Heats Up_seekingalpha.com
2023: 89bio Unveils Bullish Long-Term Data for NASH Candidate
2023: 89Bio: Risk And Reward Balance In NASH Therapeutics (NASDAQ:ETNB)
2023: 89Bio's Low Price Presents An Opportunity (NASDAQ:ETNB)
2024: 89bio lines up China CDMO to build API plant for commercial production of MASH candidate
2024: 89bio: Bullish In Light Of Further MOA Being Established By Peer
2024: 89bio: Surviving A Competitive Space - For Now
2024: Madrigal, 89Bio jump after Novo’s semaglutide shows promise in MASH
2025: 89bio: Advancement Of Pegozafermin For SHTG Is Another Path Forward_seekingalpha.com
2025: 89bio's Pegozafermin Is Now Gaining Momentum
2025: Strategic Acquisition of 89bio by Roche Highlights Promising Growth in MASH and FGF21 Market
Jumps
Finance & Acquisitions: 89bio
Key People: 89bio